Skip to main content

DexCom, Inc.

corporate_fare Company Profile

DexCom, Inc.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Stelo, a new over-the-counter glucose biosensor designed for adults with prediabetes and Type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Exchange: NASDAQSector: Industrial Applications And Services

show_chartPrice Chart

Loading chart...

feed DXCM - Latest Insights

DXCM
Mar 02, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
7
DXCM
Feb 26, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
7
DXCM
Feb 12, 2026, 5:20 PM EST
Filing Type: 10-K
Importance Score:
7
DXCM
Feb 12, 2026, 4:03 PM EST
Filing Type: 8-K
Importance Score:
7
DXCM
Jan 12, 2026, 7:30 AM EST
Filing Type: 8-K
Importance Score:
8